黄芪甲苷IV调节KATP-JNK缝隙连接信号通路减轻神经病理性疼痛
该研究在大鼠坐骨神经慢性压迫损伤(CCI)模型及C6细胞中,探讨黄芪甲苷IV(AST IV)对神经病理性疼痛的作用机制。结果显示AST IV通过调控KATP-JNK缝隙连接轴,抑制脊髓星形胶质细胞缝隙连接蛋白43磷酸化,从而减轻神经病理性疼痛。
要点
- AST IV可减轻CCI大鼠神经病理性疼痛并抑制脊髓星形胶质细胞兴奋。
- AST IV镇痛作用依赖于缝隙连接和KATP通道的完整性。
- KATP-JNK-Cx43轴是神经病理性疼痛的潜在干预靶点。
核心结论
- 坐骨神经CCI通过激活KATP/JNK信号导致脊髓缝隙连接功能障碍,参与神经病理性疼痛。
- AST IV通过调节KATP-JNK缝隙连接轴减轻神经病理性疼痛。
研究设计与样本
- 采用大鼠坐骨神经慢性压迫损伤(CCI)模型建立神经病理性疼痛,并使用C6细胞进行体外实验。
- 采用Von Frey纤维和Hargreave法测定大鼠缩足阈值,免疫荧光和蛋白质印迹检测蛋白表达。
主要发现
- AST IV显著减轻CCI大鼠神经病理性疼痛并抑制脊髓星形胶质细胞兴奋。
- AST IV的抗伤害感受效应可被缝隙连接解偶联剂CBX逆转。
- AST IV抑制CCI大鼠脊髓中磷酸化connexin 43(p-Cx43)和p-JNK的高表达。
- JNK抑制剂缓解神经病理性疼痛,该效应可被CBX逆转;JNK抑制剂降低CCI大鼠和TNF-α处理的C6细胞中p-Cx43高表达。
- AST IV的镇痛效应可被KATP通道阻断剂格列本脲逆转;格列本脲消除AST IV在体内外对p-JNK和p-Cx43的抑制作用;KATP通道开放剂在TNF-α处理的C6细胞中模拟AST IV对p-JNK和p-Cx43的抑制作用。
临床怎么用
- AST IV可能通过调控KATP-JNK缝隙连接轴成为神经病理性疼痛的潜在治疗药物。
- KATP通道和缝隙连接蛋白43的磷酸化水平可能作为神经病理性疼痛机制研究的关注点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Gap junctions play a pivotal role in contributing to the formation of astroglial networks and in chronic pain. However, the mechanisms underlying the dysfunction of astroglial gap junctions in chronic pain have not been fully elucidated. METHODS: Chronic constriction injury (CCI) of the sciatic nerve was used to establish rat neuropathic pain model. C6 cells were used to perform experiments in vitro. Von Frey hairs and Hargreave's method were used to determine the withdrawal threshold of rats. Protein expression was detected by immunofluorescence and western blotting. RESULTS: Astragaloside IV (AST IV) significantly attenuated neuropathic pain and suppressed the excitation of spinal astrocytes in rats with CCI. The antinociceptive effect of AST IV was reversed by the gap junction decoupler carbenoxolone (CBX). AST IV inhibited the high expression of phosphorylated connexin 43 (p-Cx43) and p-c-Jun N-terminal kinase (p-JNK) in spinal cord of rats with CCI. JNK inhibitor alleviated neuropathic pain, which was reversed by CBX. JNK inhibitor decreased the high expression of p-Cx43 in both rats with CCI and tumor necrosis factor-alpha (TNF-α)-treated C6 cells. Additionally, the analgesic effect of AST IV was reversed by the adenosine triphosphate-sensitive potassium (KATP) channel blocker, glibenclamide (Glib). Glib abolished the inhibitory effects of AST IV on p-JNK and p-Cx43 both in vivo and in vitro. KATP channel opener (KCO) mimicked the inhibitory effects of AST IV on p-JNK and p-Cx43 in TNF-α-treated C6 cells. CONCLUSION: Our results indicate that the sciatic nerve CCI induces the dysfunction of gap junctions in the spinal cord by activating KATP/JNK signaling to contribute to neuropathic pain. AST IV attenuates neuropathic pain via regulating the KATP-JNK gap junction axis.
引用
- Dai WL, Zhang L, Han L, et al. Regulation of the KATP-JNK gap junction signaling pathway by immunomodulator astragaloside IV attenuates neuropathic pain. Reg Anesth Pain Med. 2020. PMID: 32963077. doi:10.1136/rapm-2020-101411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。